olutasidenib,Azacitidine,Cytarabine
rigel pharma,Forma Therapeutics
['olutasidenib', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders),(-dreamlike)', 'leusm']
congress | #ash22 jorge cortes , presents interim phase ii data from study 2102-hem-101 of olutasidenib in r/r idh1-mutated aml. cr/crh rate = 35% (median duration 25.9 months) &amp; orr = 48% (n = 147). median dor = 11.7 months, os = 11.6 months. #leusm 
The AML Hub is an evidence-based online resource on Acute Myeloid Leukemia (AML), for academic researchers and treating clinicians. #leusm